Evidence map›Paper›PMID 21802442›Full record

ArticlePharmacology, biochemistry, and behavior2011

Physiological and subjective effects of acute intranasal methamphetamine during atomoxetine maintenance.

Craig R Rush, William W Stoops, Joshua A Lile, Paul E A Glaser, Lon R Hays

Open access · greenAbstract readComparative StudyControlled Clinical Trial
In one paragraph

Article in Pharmacology, biochemistry, and behavior, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.4field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Craig R RushDepartment of Behavioral Science, University of Kentucky College of Medicine, College of Medicine Office Building, Lexington, KY 40536-0086, USA. crush2@email.uky.edu
William W Stoops
Joshua A Lile
Paul E A Glaser
Lon R Hays
University of Kentucky · USWhitney Museum of American Art · US

Funding

Kentucky Center for Clinical and Translational ScienceUL1TR001998 · NCATS · UNIVERSITY OF KENTUCKY · PI HARTMANN, KATHERINE E, KERN, PHILIP A · 2016 to 2025
$34.2M
Kentucky Center for Clinical and Translational ScienceUL1TR000117 · NCATS · UNIVERSITY OF KENTUCKY · PI KERN, PHILIP A · 2012 to 2015
$13.3M
KENTUCKY CENTER FOR CLINICAL AND TRANSLATIONAL SCIENCEUL1RR033173 · NCRR · UNIVERSITY OF KENTUCKY · PI KERN, PHILIP A · 2011 to 2011
$3.5M
Agonist Replacement Therapy for Methamphetamine Dependence: Human Lab StudiesR01DA025032 · NIDA · UNIVERSITY OF KENTUCKY · PI RUSH, CRAIG R · 2009 to 2013
$1.8M
A Pharmacological Analysis of Delta 9-THC in HumansK01DA018772 · NIDA · UNIVERSITY OF KENTUCKY · PI LILE, JOSHUA ANTHONY · 2005 to 2009
$729k
NCATS NIH HHS UL1 TR000117NCATS NIH HHS UL1 TR001998NCRR NIH HHS UL1 RR033173NIDA NIH HHS K01 DA018772NIDA NIH HHS R01 DA025032
6 · The paper itself

Abstract

rationaleMethamphetamine abuse and dependence are significant public-health concerns. Behavioral therapies are effective for reducing methamphetamine use. However, many patients enrolled in behavioral therapies are unable to achieve significant periods of abstinence suggesting other strategies like pharmacotherapy are needed.

objectivesThis experiment determined the physiological and subjective effects of acutely administered intranasal methamphetamine during atomoxetine maintenance in seven non-treatment seeking stimulant-dependent participants. Atomoxetine was chosen for study because it blocks reuptake at the norepinephrine transporter and increases extracellular dopamine levels in the prefrontal cortex. In this way, atomoxetine might function as an agonist replacement therapy for stimulant-dependent patients.

methodsAfter at least 7 days of maintenance on atomoxetine (0 and 80 mg/day), participants were administered ascending doses of intranasal methamphetamine (0, 5, 10, 20 and 30 mg) across two experimental sessions. Intranasal methamphetamine doses were separated by 90 min.

resultsIntranasal methamphetamine produced prototypical physiological and subjective effects (e.g., increased heart rate, blood pressure, temperature and subjective ratings of Good Effects). Atomoxetine maintenance augmented the heart rate-increasing effects of methamphetamine, but attenuated the pressor effects. The subjective effects of intranasal methamphetamine were similar during atomoxetine and placebo maintenance.

conclusionsThese results suggest that methamphetamine can be safely administered to participants maintained on atomoxetine, but whether it might be an effective pharmacotherapy for methamphetamine dependence remains to be determined.

Indexed as

Administration, IntranasalAtomoxetine HydrochlorideBlood PressureDose-Response Relationship, DrugDouble-Blind MethodDrug Therapy, CombinationHeart RateHumansMethamphetaminePropylaminesPsychomotor PerformanceTime FactorsAtomoxetine HydrochlorideMethamphetaminePropylamines

Identifiers

PMID21802442
PMCPMC3183234
OpenAlexW2094518279

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.